These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30371861)

  • 1. Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study.
    Grimsrud KN; Ivanova X; Sherwin CM; Palmieri TL; Tran NK
    J Burn Care Res; 2019 Jan; 40(1):91-96. PubMed ID: 30371861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.
    Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients.
    Grimsrud KN; Lima KM; Tran NK; Palmieri TL
    J Burn Care Res; 2020 Jan; 41(1):8-14. PubMed ID: 31538188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl clearance and volume of distribution are increased in patients with major burns.
    Han T; Harmatz JS; Greenblatt DJ; Martyn JA
    J Clin Pharmacol; 2007 Jun; 47(6):674-80. PubMed ID: 17428913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl requirements.
    Tan PC; Hassan SK; Mohamad NA; Gan SH
    J Clin Pharm Ther; 2012 Feb; 37(1):100-4. PubMed ID: 21128989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients.
    Wu SB; Cai LN; Yang XH; Fu HG; Sun K; Yuan F; Dong TL
    Genet Test Mol Biomarkers; 2015 May; 19(5):248-52. PubMed ID: 25825958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children.
    Hagos FT; Horvat CM; Au AK; Conley YP; Li L; Poloyac SM; Kochanek PM; Clark RSB; Empey PE
    Clin Pharmacokinet; 2019 Dec; 58(12):1567-1576. PubMed ID: 31168770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interaction of opioid analgesics at the level of biotransformation].
    Petri H; Grandt D
    Schmerz; 2016 Dec; 30(6):519-525. PubMed ID: 27439327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug interactions of synthetic opiate analgesics.
    Armstrong SC; Wynn GH; Sandson NB
    Psychosomatics; 2009; 50(2):169-76. PubMed ID: 19377028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil.
    Guitton J; Buronfosse T; Désage M; Lepape A; Brazier JL; Beaune P
    Biochem Pharmacol; 1997 Jun; 53(11):1613-9. PubMed ID: 9264313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
    VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
    Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period.
    Tanaka N; Naito T; Yagi T; Doi M; Sato S; Kawakami J
    Ther Drug Monit; 2014 Jun; 36(3):345-52. PubMed ID: 24365989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation.
    Cambic CR; Avram MJ; Gupta DK; Wong CA
    Int J Obstet Anesth; 2014 Feb; 23(1):45-51. PubMed ID: 24333052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
    Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
    Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
    J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP3A4*18B polymorphisms and interactions with OPRM1 A118G on postoperative fentanyl requirements in patients undergoing radical gastrectomy.
    Liao Q; Chen DJ; Zhang F; Li L; Hu R; Tang YZ; Ou-Yang W; Huang D
    Mol Med Rep; 2013 Mar; 7(3):901-8. PubMed ID: 23313934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
    Swaisland HC; Cantarini MV; Fuhr R; Holt A
    Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.